Premium
BAX / BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia
Author(s) -
Sharawat Surender Kumar,
Bakhshi Radhika,
Vishnubhatla Sreenivas,
Gupta Ritu,
Bakhshi Sameer
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24518
Subject(s) - medicine , taqman , flow cytometry , myeloid leukemia , leukemia , gastroenterology , myeloid , cytogenetics , real time polymerase chain reaction , microbiology and biotechnology , immunology , gene , biology , genetics , chromosome
BAX / BCL2 ratio in pediatric AML has not been evaluated. In this first prospective study, we evaluated BAX / BCL2 transcript and RMFI ratio in 64 patients using real‐time PCR (TaqMan Probe chemistry) and flow‐cytometry, respectively. There was no correlation of BAX / BCL2 transcript ratio with RMFI ratio (R = −0.05; P = 0.715). Patients with WBC count >50,000/mm 3 had lower BAX / BCL2 RMFI ratio ( P = 0.043), whereas no difference in ratio was observed among patients of different cytogenetics subgroups ( P = 0.786). Higher BAX / BCL2 RMFI ratio was associated positively with CR rate ( P = 0.03), but this study was unable to show that it translated into improved EFS or OS. Pediatr Blood Cancer 2013;60E63‐E66. © 2013 Wiley Periodicals, Inc.